

(Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

5

Complete if Known

Application Number	10/591,195
Filing Date	September 29, 2006
First Named Inventor	Liat Hayardeny
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	68051-B-PCT-US/JPW

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
1	US- 5,800,808	09-01-1998	Konfino, et al.		
2	US- 5,981,589	11-09-1999	Konfino, et al.		
3	US- 6,048,898	04-11-2000	Konfino, et al.		
4	US- 6,054,430	04-25-2000	Konfino, et al.		
5	US- 6,214,791	04-10-2001	Aron, et al.		
6	US- 6,342,476	01-29-2002	Konfino, et al.		
7	US- 6,362,161	03-26-2002	Konfino, et al.		
8	US- 6,514,938	02-04-2003	Gad, et al.		
9	US- 6,620,847	09-16-2003	Konfino, et al.		
10	US- 6,800,285	10-05-2004	Rodriguez		
11	US- 6,800,287	10-05-2004	Gad, et al.		
12	US- 6,939,539	09-06-2005	Konfino, et al.		
13	US- 7,022,663	04-04-2006	Gilbert, et al.		
14	US- 7,033,582	04-25-2006	Yong, et al.		
15	US- 7,074,580	07-22-2006	Gad, et al.		
16	US- 7,163,802 B2	01-16-2007	Gad, et al.		
17	US- 7,199,098	04-03-2007	Konfino, et al.		
18	US- 7,279,172	10-09-2007	Aharoni, et al.		
19	US- 2003-0170729 A1	09-11-2003	Klinger		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
29	WO 98/30227		07-16-1998	Yeda Research and Development CO., LTD.		
30	WO 00/05250		02-03-2000	Yeda Research and Development CO., LTD.		
31	WO 00/18794		04-06-2000	Yeda Research and Development CO., LTD.		
32	WO 00/27417		05-18-2000	Yeda Research and Development CO., LTD.		
33	WO 01/60392		08-23-2001	Yeda Research and Development CO., LTD.		
34	WO 01/93828		12-13-2001	Teva Pharmaceuticals Industries, LTD.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: Liat Hayardeny, et al.
Filed: §371 national stage of PCT
International Application No.
PCT/US2005/007072, filed March 3,
2005
ExhibitA

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 5

Application Number	10/591,195
Filing Date	September 29, 2006
First Named Inventor	Liat Hayardeny
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	68051-B-PCT-US/JPW

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ³ (if known)			
20	US	2005-0170004	08-04-2005	Rosenberger	
21	US	2006-0122113	06-08-2006	Pinchasi, et al.	
22	US	2006-0172942 A1	08-03-2006	Dolitzky	
23	US	2006-0052586	03-09-2006	Dolitzky	
24	US	2007-0021341 A1	01-25-2007	Sela, et al.	
25	US	2007-0021324 A1	01-25-2007	Dolitzky, et al.	
26	US	2007-0048794 A1	03-01-2007	Gad, et al.	
27	US	2007-0054857	03-08-2007	Pinchasi, et al.	
28	US	11/590,338	10-30-2006	Pinchasi, et al.	
	US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
35	WO	01/97846	12-27-2001	Teva Pharmaceuticals Industries, LTD.		
36	WO	03/048735	06-12-2003	Teva Pharmaceuticals Industries, LTD.		
59	WO	04/43995	05-27-2004	APOTEX PHARMACHEM INC.		
60	WO	06/50122	05-11-2006	Sandoz AG		
61	WO	08/06026	01-10-2008	MOMENTA PHARMACEUTICALS, INC.		

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, 6000 DODGE STREET, ALEXANDRIA, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/591,195
				Filing Date	September 29, 2006
				First Named Inventor	Liat Hayardeny
				Art Unit	1649
				Examiner Name	Kolker, Daniel E.
Sheet	3	of	5	Attorney Docket Number	68051-B-PCT-US/JPW

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	37	Bornstein et al., "Treatment of MS with a Synthetic Polypeptide: Preliminary Results" Ann. Neurol., 1980, 8, 117		
	38	Bornstein et al., "Treatment of MS with synthetic polypeptide: preliminary results" Trans. Am. Neurol. Assoc., 1980, 105, 348-350		
	39	Bornstein et al., "MS: Trial of a synthetic polypeptide" Ann. Neurol., 1982, 11, 317-319		
	40	Bornstein et al., "Clinical trials of Copolymer 1 in MS" Ann. N.Y. Acad. Sci. (USA), 1984, 366-372		
	41	Bornstein et al., "Clinical Trials of a synthetic polypeptide (Copolymer 1) for the treatment of MS" Immunol. & Clin. Aspects of MS, 1984, 144-150		
	42	Bornstein et al., "MS: Clinical Trials of a Synthetic Polypeptide, Copolymer 1" Neurol., 1985, 35 (Suppl. 1), 103		
	43	Bornstein, "Cop 1 may be beneficial for patients with exacerbating remitting form of MS" Adv. Ther., 1987, 4, 206		
	44	Bornstein, et al., "A Pilot trial of Cop 1 in Exacerbating remitting MS" New Eng. J. Med., 1987, 317 (7), 408-414		
	45	Bornstein, et al., "Clinical Experience with COP-1 in MS" Neurol., 1988, 38 (Suppl. 2.), 66-69		
	46	Bornstein, et al., "Rationale for Immunomodulating Therapies of MS" Neurol., 1988, 38 (Suppl. 2.), 80-81R		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/591,195
				Filing Date	September 29, 2006
				First Named Inventor	Liat Hayardeny
				Art Unit	1649
				Examiner Name	Kolker, Daniel E.
Sheet	4	of	5	Attorney Docket Number	68051-B-PCT-US/JPW

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	47	Bornstein et al., "Pilot Trial of COP-1 in Chronic Progressive MS: Preliminary report" Intl. MS Conf. 1988, in Elsevier Sci. Publi. 1989, 225-232	
	48	Bornstein et al., "Clinical Trials of Cop 1 in MS" Handbook of MS, 1990, 469-480	
	49	Bornstein et al., "A Placebo-controlled, Double-Blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive MS" Neurol., 1991, 41, 533-539	
	50	Bornstein et al., "Treatment of MS with Copolymer 1" Treatmt. of MS, Trial Design., 1992, 173-198US5,800,808	
	51	Bornstein, "Clinical Experience: Hopeful Prospects in MS," Hosp Prac. (Off. Ed.) May 15, 1992 vol. 27 (No. 5) L135-138, 141-142, 145-158	
	52	Kalkers et al., "The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study" in Multiple Sclerosis, 2002, vol. 8, issue 6, pages 532-533	
	53	Sela et al., "Glatiramer acetate in the treatment of multiple sclerosis" in Expert Opin. Pharmacother., 2001, vol.2, no.7, pages 1149-1165	
	54	Copaxone® (glatiramer acetate injection), prescribing information, http://www.copaxone.com/pdf/PrescribingInformation.pdf	
	55	International Preliminary Report on Patentability issued by the International Bureau of WIPO dated December 24, 2007 in connection with International Application No. PCT/US2005/0007072	
	56	PCT International Search Report issued November 30, 2007 for International Application Publication No. PCT/US2005/0007072	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/591,195
				Filing Date	September 29, 2006
				First Named Inventor	Liat Hayardeny
				Art Unit	1649
				Examiner Name	Kolker, Daniel E.
Sheet	5	of	5	Attorney Docket Number	68051-B-PCT-US/JPW

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	57	Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/AU) on November 30, 2007 in connection with International Application No. PCT/US2005/0007072				
	58	"COPAXONE®" in <u>Physician's Desk Reference</u> , Medical Economics Co., Inc., Montvale, NJ, 2002, 3115				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.